1. Home
  2. CASH vs VRDN Comparison

CASH vs VRDN Comparison

Compare CASH & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CASH
  • VRDN
  • Stock Information
  • Founded
  • CASH 1954
  • VRDN 2006
  • Country
  • CASH United States
  • VRDN United States
  • Employees
  • CASH N/A
  • VRDN N/A
  • Industry
  • CASH Major Banks
  • VRDN Medical Specialities
  • Sector
  • CASH Finance
  • VRDN Health Care
  • Exchange
  • CASH Nasdaq
  • VRDN Nasdaq
  • Market Cap
  • CASH 1.7B
  • VRDN 1.6B
  • IPO Year
  • CASH N/A
  • VRDN N/A
  • Fundamental
  • Price
  • CASH $69.94
  • VRDN $15.81
  • Analyst Decision
  • CASH Hold
  • VRDN Buy
  • Analyst Count
  • CASH 3
  • VRDN 12
  • Target Price
  • CASH $79.67
  • VRDN $36.44
  • AVG Volume (30 Days)
  • CASH 186.5K
  • VRDN 888.0K
  • Earning Date
  • CASH 04-23-2025
  • VRDN 05-07-2025
  • Dividend Yield
  • CASH 0.29%
  • VRDN N/A
  • EPS Growth
  • CASH 12.58
  • VRDN N/A
  • EPS
  • CASH 6.88
  • VRDN N/A
  • Revenue
  • CASH $719,617,000.00
  • VRDN $302,000.00
  • Revenue This Year
  • CASH $12.98
  • VRDN N/A
  • Revenue Next Year
  • CASH $5.72
  • VRDN $17,629.40
  • P/E Ratio
  • CASH $10.16
  • VRDN N/A
  • Revenue Growth
  • CASH 9.58
  • VRDN N/A
  • 52 Week Low
  • CASH $46.68
  • VRDN $11.40
  • 52 Week High
  • CASH $86.00
  • VRDN $27.20
  • Technical
  • Relative Strength Index (RSI)
  • CASH 29.66
  • VRDN 44.43
  • Support Level
  • CASH $69.50
  • VRDN $14.98
  • Resistance Level
  • CASH $72.44
  • VRDN $17.00
  • Average True Range (ATR)
  • CASH 2.02
  • VRDN 0.91
  • MACD
  • CASH -0.71
  • VRDN 0.18
  • Stochastic Oscillator
  • CASH 4.97
  • VRDN 59.66

About CASH Pathward Financial Inc.

Pathward Financial Inc is a unitary savings and loan holding company. It's a wholly owned full-service banking subsidiary of Meta Financial, is both a community-oriented financial institution offering a variety of financial services to meet the needs of the communities it serves, and a payments company providing services on a nationwide basis. It operates through three reportable segments: Consumer: The Consumer segment includes the Partner Solutions business line, which collaborates with partners to navigate payment and lending needs; Commercial: The Commercial segment includes the Company's Commercial Finance business line, which helps businesses access funds needed to launch, operate, and grow; and Corporate Services. The majority of the revenue is generated from Consumer segment.

About VRDN Viridian Therapeutics Inc.

Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease.

Share on Social Networks: